Literature DB >> 20152222

Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).

Nancy M Albert1, Gregg C Fonarow, Clyde W Yancy, Anne B Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J Thomas Heywood, Mark McBride, Mandeep R Mehra, Christopher M O'Connor, Dwight Reynolds, Mary Norine Walsh.   

Abstract

BACKGROUND: National guidelines recommend heart failure (HF) disease management programs to facilitate adherence to evidence-based practices. This study examined the influence of dedicated HF clinics on delivery of guideline-recommended therapies for cardiology practice outpatients with HF and reduced left ventricular ejection fraction.
METHODS: IMPROVE HF, a prospective cohort study, enrolled 167 cardiology practices to characterize outpatient management of 15,381 patients with chronic systolic HF. Adherence to guideline-recommended HF therapies was recorded, and the presence of a dedicated HF clinic was assessed by survey. Multivariate models identified contributions to delivery of guideline-recommended HF therapies.
RESULTS: Of practices, 41.3% had a dedicated HF clinic. Practices with a dedicated HF clinic had greater adherence to 3 of 7 guideline-recommended HF therapy measures: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (P = .02), beta-blocker (P = .025), and HF education (P = .009). After adjustment, use of a dedicated HF clinic was associated with greater conformity in 2 of 7 measures: cardiac resynchronization therapy (P = .036) and HF education (P = .005) but not angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, aldosterone antagonist, implantable cardioverter-defibrillator therapy, and anticoagulation for atrial fibrillation.
CONCLUSIONS: Use of dedicated HF clinics varied in cardiology outpatient practices and was associated with greater use of cardiac resynchronization therapy and HF education but not other guideline-recommended therapies. Copyright (c) 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20152222     DOI: 10.1016/j.ahj.2009.11.022

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.

Authors:  Miriam S Jacob; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2011-03

2.  Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure.

Authors:  C Zugck; J Franke; G Gelbrich; L Frankenstein; T Scheffold; S Pankuweit; H D Duengen; V Regitz-Zagrosek; B Pieske; T Neumann; M Rauchhaus; C E Angermann; H A Katus; G E Ertl; S Störk
Journal:  Clin Res Cardiol       Date:  2011-12-03       Impact factor: 5.460

3.  A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting.

Authors:  Jennifer Franke; Christian Zugck; Jan Sebastian Wolter; Lutz Frankenstein; Matthias Hochadel; Philipp Ehlermann; Ralph Winkler; Manfred Nelles; Ralf Zahn; Hugo A Katus; Jochen Senges
Journal:  Clin Res Cardiol       Date:  2011-07-27       Impact factor: 5.460

4.  Nurse-Led Multidisciplinary Heart Failure Group Clinic Appointments: Methods, Materials, and Outcomes Used in the Clinical Trial.

Authors:  Carol E Smith; Ubolrat Piamjariyakul; Kathleen M Dalton; Christy Russell; Jo Wick; Edward F Ellerbeck
Journal:  J Cardiovasc Nurs       Date:  2015 Jul-Aug       Impact factor: 2.083

5.  Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry.

Authors:  W von Scheidt; C Zugck; M Pauschinger; R Hambrecht; O Bruder; A Hartmann; M Rauchhaus; R Zahn; J Brachmann; U Tebbe; T Neumann; R H Strasser; M Böhm; S Störk; M Hochadel; P Heidemann; J Senges
Journal:  Clin Res Cardiol       Date:  2014-07-23       Impact factor: 5.460

6.  The value of INnovative ICT guided disease management combined with Telemonitoring in OUtpatient clinics for Chronic Heart failure patients. Design and methodology of the IN TOUCH study: a multicenter randomised trial.

Authors:  Arjen E de Vries; Richard M de Jong; Martje H L van der Wal; Tiny Jaarsma; Rene B van Dijk; Hans L Hillege
Journal:  BMC Health Serv Res       Date:  2011-07-13       Impact factor: 2.655

7.  A Novel Intelligent Two-Way Communication System for Remote Heart Failure Medication Uptitration (the CardioCoach Study): Randomized Controlled Feasibility Trial.

Authors:  Christophe Jp Smeets; Valerie Storms; Pieter M Vandervoort; Pauline Dreesen; Julie Vranken; Marita Houbrechts; Hanne Goris; Lars Grieten; Paul Dendale
Journal:  JMIR Cardio       Date:  2018-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.